BioPortUSA has established a new strategic partnership with Kalms Consulting. The company provides expert, hands-on guidance for medical device, diagnostics, biotech, health IT, pharmaceutical and other healthcare companies in the areas of market access, health economics, reimbursement and business development. Marco Kalms, the founder of Kalms stated that “having BioPortUSA as our strategic alliance partner in the USA provides us with a base to build our European business platform on as well as facilitate transactions for our clients beyond our core competency thus enhancing our value proposition.”
Kalms’s network extends beyond Germany allowing BioPort to play an even larger role in supporting market entry for international life science companies wishing to enter the USA. “We look forward to working with our new found partner Kalms Consulting to provide a comprehensive overview of all facets involved with Market Entry into the US Healthcare Market but especially in the area of market access and reimbursement” said Mark Lesselroth, CEO of BioPortUSA. The two companies are planning a joint workshop in Berlin later this year to help explain the differences between Market Access in Europe vs the USA.